Literature DB >> 25609157

RANKL and OPG gene polymorphisms: associations with vertebral fractures and bone mineral density in premenopausal systemic lupus erythematosus.

A C Bonfá1, L P C Seguro, V Caparbo, E Bonfá, R M R Pereira.   

Abstract

UNLABELLED: Premenopausal women with systemic lupus erythematosus (SLE) have a higher prevalence of low bone mineral density and vertebral fractures. Multiple genetic loci for osteoporotic fracture were identified in recent genome-wide association studies. This study provides a novel data demonstrating that receptor activator of NF-κB ligand (RANKL)/osteoprotegerin (OPG) polymorphisms likely plays an important role in the bone remodeling process in SLE premenopausal women.
INTRODUCTION: The purpose of this study was to evaluate single-nucleotide polymorphisms (SNPs) of the RANKL, RANK, and OPG genes in premenopausal SLE patients and their association with sRANKL and OPG serum levels, vertebral fractures, and bone mineral density (BMD).
METHODS: A total of 211 premenopausal SLE patients (American College of Rheumatology (ACR) criteria) and 154 healthy controls were enrolled. SNPs of RANKL 290A>G (rs2277438), OPG 1181G>C (rs2073618), 245T>G (rs3134069), 163A>G (rs3102735), and RANK A>G (rs3018362) were obtained by real-time PCR. sRANKL/OPG serum levels were determined by ELISA. BMD and vertebral fractures were evaluated by dual-energy X-ray absorptiometry (DXA).
RESULTS: SLE patients and controls had similar frequencies of the RANKL 290 G allele (p = 0.94), OPG 1181 C allele (p = 0.85), OPG 245 G allele (p = 0.85), OPG 163 G allele (p = 0.78), and RANK G allele (p = 0.87). Further analysis of the SLE patients revealed that the frequency of the RANKL 290 G allele was lower in patients with fractures than that in patients without fractures (28.1 vs 46.9%, p = 0.01). In addition, the frequency of the OPG 245 G allele was higher in patients with low BMD than that in patients with normal BMD (31.4 vs 18.1%, p = 0.04). No association of OPG 1181 G>C, OPG 163 A>G, and RANK A>G SNPs with BMD/fractures was found. Additionally, no association was observed between RANKL/OPG/RANK SNPs and sRANKL/OPG serum levels.
CONCLUSIONS: Our study provides novel data demonstrating that RANKL/OPG genetic variations appear to play a role in bone remodeling, particularly in its major complication, fracture, in premenopausal patients with SLE.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25609157     DOI: 10.1007/s00198-015-3029-x

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  35 in total

Review 1.  Management of osteoporosis in a pre-menopausal woman.

Authors:  Ashok K Bhalla
Journal:  Best Pract Res Clin Rheumatol       Date:  2010-06       Impact factor: 4.098

2.  A functional RANKL polymorphism associated with younger age at onset of rheumatoid arthritis.

Authors:  Wenfeng Tan; Hui Wu; Jian Zhao; Lezlie A Derber; David M Lee; Nancy A Shadick; Doyt L Conn; Edwin A Smith; Vivian H Gersuk; Gerald T Nepom; Larry W Moreland; Daniel E Furst; Susan D Thompson; Beth L Jonas; V Michael Holers; David N Glass; Pojen P Chen; S Louis Bridges; Michael E Weinblatt; Harold E Paulus; Betty P Tsao
Journal:  Arthritis Rheum       Date:  2010-10

3.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

Review 4.  Therapy Insight: osteoporosis and osteonecrosis in systemic lupus erythematosus.

Authors:  Nancy E Lane
Journal:  Nat Clin Pract Rheumatol       Date:  2006-10

5.  Increasing age-adjusted risk of fragility fractures: a sign of increasing osteoporosis in successive generations?

Authors:  K J Obrant; U Bengnér; O Johnell; B E Nilsson; I Sernbo
Journal:  Calcif Tissue Int       Date:  1989-03       Impact factor: 4.333

Review 6.  RANK, RANKL and osteoprotegerin in arthritic bone loss.

Authors:  M C Bezerra; J F Carvalho; A S Prokopowitsch; R M R Pereira
Journal:  Braz J Med Biol Res       Date:  2005-02-15       Impact factor: 2.590

Review 7.  Genetic profiling and individualized assessment of fracture risk.

Authors:  Tuan V Nguyen; John A Eisman
Journal:  Nat Rev Endocrinol       Date:  2013-02-05       Impact factor: 43.330

8.  Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.

Authors:  Jung Gu Kim; Jung Hwa Kim; Ja Yeon Kim; Seung Yup Ku; Byung Chul Jee; Chang Suk Suh; Seok Hyun Kim; Young Min Choi
Journal:  Menopause       Date:  2007 Sep-Oct       Impact factor: 2.953

Review 9.  Management of women with systemic lupus erythematosus.

Authors:  Preeta Kaur Chugh
Journal:  Maturitas       Date:  2013-04-28       Impact factor: 4.342

10.  "Single nucleotide polymorphisms of the OPG/RANKL system genes in primary hyperparathyroidism and their relationship with bone mineral density".

Authors:  María Piedra; María T García-Unzueta; Ana Berja; Blanca Paule; Bernardo A Lavín; Carmen Valero; José A Riancho; José A Amado
Journal:  BMC Med Genet       Date:  2011-12-20       Impact factor: 2.103

View more
  17 in total

Review 1.  Fracture risk and bone mineral density levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis.

Authors:  X Wang; S Yan; C Liu; Y Xu; L Wan; Y Wang; W Gao; S Meng; Y Liu; R Liu; D Xu
Journal:  Osteoporos Int       Date:  2016-01-11       Impact factor: 4.507

2.  Osteoprotegerin polymorphisms are associated with alcohol-induced osteonecrosis of femoral head in Chinese Han population from Henan province.

Authors:  Yizhou Li; Yongchang Guo; Quanjian Wang; Yongri Ouyang; Yuju Cao; Tianbo Jin; Jianzhong Wang
Journal:  J Genet       Date:  2016-12       Impact factor: 1.166

3.  Associations between OPG and RANKL polymorphisms, vertebral fractures, and abdominal aortic calcification in community-dwelling older subjects: the Sao Paulo Ageing & Health Study (SPAH).

Authors:  R M R Pereira; C P Figueiredo; C C Cha; V F Caparbo; R M Oliveira; A S Franco; P R Menezes; I de Castro; L F Onuchic
Journal:  Osteoporos Int       Date:  2016-06-16       Impact factor: 4.507

4.  Osteoprotegerin Gene (OPG) Polymorphisms Associated with Peri-implantitis Susceptibility in a Chinese Han Population.

Authors:  Jian Zhou; Yimin Zhao
Journal:  Med Sci Monit       Date:  2016-11-09

5.  Common Variants in OPG Confer Risk to Bone Mineral Density Variation and Osteoporosis Fractures.

Authors:  Xiaoyong Sheng; Guangyong Cai; Xingjun Gong; Zouying Yao; Ye Zhu
Journal:  Sci Rep       Date:  2017-05-11       Impact factor: 4.379

6.  OPG and RANKL polymorphisms are associated with alcohol-induced osteonecrosis of the femoral head in the north area of China population in men.

Authors:  Yizhou Li; Yuan Wang; Yongchang Guo; Quanjian Wang; Yongri Ouyang; Yuju Cao; Tianbo Jin; Jianzhong Wang
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

Review 7.  Genetic Factors in Systemic Lupus Erythematosus: Contribution to Disease Phenotype.

Authors:  Fulvia Ceccarelli; Carlo Perricone; Paola Borgiani; Cinzia Ciccacci; Sara Rufini; Enrica Cipriano; Cristiano Alessandri; Francesca Romana Spinelli; Antonio Sili Scavalli; Giuseppe Novelli; Guido Valesini; Fabrizio Conti
Journal:  J Immunol Res       Date:  2015-12-21       Impact factor: 4.818

Review 8.  Osteoprotegerin rich tumor microenvironment: implications in breast cancer.

Authors:  Sudeshna Goswami; Neelam Sharma-Walia
Journal:  Oncotarget       Date:  2016-07-05

9.  Sclerostin induced tumor growth, bone metastasis and osteolysis in breast cancer.

Authors:  Menghai Zhu; Changzhen Liu; Shifei Li; Shudong Zhang; Qi Yao; Qingkun Song
Journal:  Sci Rep       Date:  2017-09-12       Impact factor: 4.379

10.  Genetic Variation and Hot Flashes: A Systematic Review.

Authors:  Carolyn J Crandall; Allison L Diamant; Margaret Maglione; Rebecca C Thurston; Janet Sinsheimer
Journal:  J Clin Endocrinol Metab       Date:  2020-12-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.